-
CXCL11 and CXCR3alt levels predict which bladder cancer patients respond to chemotherapy
Time of Update: 2021-01-22
be completely abandoned and transferred directly to the surgical removal of bladder cancer. this personalized approach not only saves patients from the side effects of ineffective chemotherapy, but may also increase their chances of survival
-
The molecular characteristics of liver metastasis in pancreatic cancer were deciphered
Time of Update: 2021-01-22
, puncture samples, or autopsy samples. these samples helped to explore the molecular mechanisms of pancreatic cancer metastasis, the information provided was limited, especially in the analysis of the characteristics of the transfer cooker
-
Cell: Reveals the molecular mechanism of antiviral immune response in targeted tumors in triple-negative breast cancer
Time of Update: 2021-01-22
'Our study reveals a new way to activate the body's inflammatory response by specifically targeting cancer cells,' said Dr. Elizabeth Bowling, .
-
"Elimination of cervical cancer" health science tour launched
Time of Update: 2021-01-22
that although the HPV vaccine has not yet been included in the immunization program at the national level, but some parts of China have appeared "pioneers", it can be foreseen that the future domestic HPV vaccine penetration rate will continue to improve
-
Gastric Cancer: Effects of postoperative complications on survival outcomes in patients with stomach cancer
Time of Update: 2021-01-22
study concluded that postoperative complications can adversely affect the long-term survival of patients with cT3/4a stomach cancer.
-
New study: Uncover the molecular mechanisms by which ovarian cancer cells adapt to their surroundings to promote tumor growth
Time of Update: 2021-01-22
, a mechanism that allows cancer cells to escape the most commonly used treatments in ovarian cancer patients, thereby promoting the proliferation of cancer cells. may help researchers develop new treatments for ovarian cancer. The researchers
-
Sci Adv: Research reveals new ways to treat chemotherapy-resistant breast cancer
Time of Update: 2021-01-22
January 20, 2021 /--- In a recent study, scientists discovered a molecule that selectively kills specific breast cancer subtypes that are difficult to treat, potentially lead to a new treatment.
-
Eur Radiol: How effective is palliative TACE treatment in patients with hepatocellular liver cancer who combine blood vessels?
Time of Update: 2021-01-22
In the training group and the validation group total lifetime dependence ROC curve this study showed that TACE was effective in liver cancer patients who partially violated HV or IVC.
-
Has there been no new option for first-line treatment of stomach cancer for more than a decade?
Time of Update: 2021-01-22
Said Prime said it would conduct a global Phase 3 clinical trial to further test the efficacy of this combination of first-line treatments for FGFR2b-positive gastric cancer patients.
-
Roche's "T-A" program significantly improved the overall survival of patients with liver cancer
Time of Update: 2021-01-22
joint program was officially approved in China and has now been listed as a recommended therapy by several authoritative clinical guidelines, which fully demonstrates the breakthrough significance of this joint treatment. It is worth mentioning
-
Scientists have found new targets for treating lung metastasis in breast cancer
Time of Update: 2021-01-22
death in the three-negative breast cancer subtype, which is currently the least effective treatment. The research team of Hu Guohong of the Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences found that tissue protease
-
Gastric Cancer: Effects of different anticoagulants on the risk of delayed bleeding after endoscopic mucosa peeling
Time of Update: 2021-01-22
multivariable analysis in patients receiving DOAC, and the treatment of the dabiga group was associated with a significant reduction in the risk of delayed bleeding.
-
HER2 Plus Breast Cancer: The "Land of Dragons" for Domestic ADC Drugs?
Time of Update: 2021-01-22
for the development of monoclonal antibody drugs over the next decade, especially in the field of tumor-targeted therapy. the global ADC market is expected to reach $12.9 billion in 2024, with a compound annual growth rate of about 35% between 2018
-
Don't eat while it's hot, be careful of esophageal cancer
Time of Update: 2021-01-22
Original title: Don't "eat while hot", watch out for esophageal cancer as the saying goes, "people eat for the day", Chinese love to eat, in daily life, many people eat also like to "eat while hot". For example, love to drink kung fu tea tide
-
Accurate treatment of lung cancer! Redding Pharmaceuticals/Cullinan Oncology achieves exclusive
Time of Update: 2021-01-21
and EU earlier this month and at the end of the month. other areas of focus include poziotinib (poziotini, green leaf pharmaceutical rights in China) and TAK-788 (mobocertinib, Takeda), which has been included in the "breakthrough treatment drug
-
Drug K approved for treatment of triple negative breast cancer in combination with chemotherapy to reduce the risk of disease progression by 35%
Time of Update: 2021-01-21
/>, Senior Vice President and Head of Global Clinical Development and Chief Medical Officer of Mercedon Laboratories, added. Keytruda combined chemotherapy as a new pre-surgery ancillary therapy (neoadjuvant) and single drug as an after-surgery
-
Nature Sub-Journal: Challenge Three Negative Breast Cancers! The new cancer vaccine is effective in preventing recurrence
Time of Update: 2021-01-21
, mice that received GM-CSF and amycin-iRGD binding gels showed significantly better drug permeability to tumors, increased cancer cell death, and fewer lung metastasis tumors than those who received gels containing amycin-iRGD, unmodified amycin
-
Research and development daily CDK4/6 inhibitors compete for early stage breast cancer: why Abesili came out on top
Time of Update: 2021-01-21
-818 treatment SLE Ib/IIa phase clinical trial November 16, Compu Biopharmaceutical Technology (Shanghai) Co., Ltd. ("Compu Biopharmaceuticals") announced that KPG-818 treatment system lupus (SLE) IB/IIa phase multi-center, randomized, double-blind
-
End of 2020: Cancer immunotherapy's heavyweight research findings read!
Time of Update: 2021-01-21
; now they can not only identify a new method that uses MEK1/2 inhibitors to reprogram T cells into TSCM cells, but also identify new molecular mechanisms induced by TSCMs. Cell: New Anti-Tumor Immunotherapy! Targeting Sb9 proteins directly kills
-
Cancer Discovery Interpretation! Uncover a new mechanism for cancer cells to evade host immune
Time of Update: 2021-01-21
Center revealed new molecular mechanisms for cancer cells to evade the immune defenses of host bodies, and the findings could help develop new treatments for cancer. We all know that cancer cells are known for spreading genetic confusion
